Design and implement a smart system to detect intruders and firing using IOT

The security system is essential for occupants' convenience and protection from intruders and fire. Theft and fire are the most important requirement for the security system. The advancement of wireless sensor networks using IOTs increased the features in a security system and play an important role in daily life. In this paper, the proposed system is divided into two units. The first one about security which use to take snapshots by a camera whenever there is fire or intruders in the security zone and mail it to the owner every three seconds by using Arduino configured with MATLAB program. MATLAB program plays the main role to coordinate between sensors and to turn on/off the cameras. The second unit is about controlling the appliances and also the main door by using AVR microcontroller configured by CVAVR software that connected with Bluetooth sensor and controlled by a smartphone by using the implementation software built-up in the smartphone. To arrival of the control unit, the user should send code from the software implementation to the framework that use to turn on /off the devices or open/close the door. This proposed system is designed and implemented in details in this paper

The efficient interleaving of digital-video-broadcasting-satellite 2nd generations system

The DVB-S2 system is designed as a toolbox to permit the execution of the satellite programs. Interleaver is an essential part of the DVB-S2 system. The current general block interleaver in DVB-S2 is not best, which leads to high BER and maybe not satisfy the requirements of the system. The purpose of this paper is to study the several interleaver types and comparative analyses are done between them to find which of these give better performance. Simulations results obtained prove that the 2D interleavers minimize BER more than other interleavers of DVB-S2. Further, the performance of 2D interleaver is better on a system that required a low SNR

Clinical profile and mortality of ST-Segment elevation myocardial- infarction patients receiving thrombolytic -Therapy in the Middle East

Objective: Little is known about thrombolytic therapy patterns in patients with ST-elevation myocardial infarction (STEMI) in the Middle East. The objective of this study was to evaluate the clinical profile and mortality of STEMI patients who arrived in hospital within 12 hours from pain onset and received thrombolytic therapy. Patients and Methods: This was a prospective, multinational, multi-centre, observational survey of consecutive acute coronary syndrome patients admitted to 65 hospitals in six Middle Eastern countries during the period between October 2008 and June 2009, as part of Gulf RACE-II (Registry of Acute Coronary Events). Analyses were performed using univariate statistics. Results: Out of 2,465 STEMI patients, 66% (n = 1,586) were thrombolysed with namely: streptokinase (43%), reteplase (44%), tenecteplase (10%), and alteplase (3%). 22.7% received no reperfusion. Median age of the study cohort was 50 (45-59) years with majority being males (91%). The overall median symptom onset-to-presentation and door-to-needle times were 165 (95- 272) minutes and 38 (24-60) minutes, respectively. Generally, patients presenting with higher GRACE risk scores were treated with newer thrombolytic agents (reteplase and tenecteplase) (P < 0.001). The use of newer thrombolytic agents was associated with a significantly lower mortality at both 1-month (0.8% vs. 1.7% vs. 4.2%; P = 0.014) and 1-year (0% vs. 1.7% vs. 3.4%; P = 0.044) compared to streptokinase use. Conclusions: Majority of STEMI patients from the Middle East were thrombolysed with streptokinase and reteplase in equal numbers. Nearly one-fifth of patients did not receive any reperfusion therapy. There was inappropriately long symptom-onset to hospital presentation as well as door-to-needle times. Use of newer thrombolytic agents in high risk patients was appropriate. Newer thrombolytic agents were associated with significantly lower mortality at 1-month and 1-year compared to the older agent, streptokinase